Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer

AI Briefing

• – Sidewinder Therapeutics raises $137M in Series B funding to develop precision bispecific ADCs for cancer treatment.
• – The financing will support the advancement of the company's pipeline of bispecific ADCs into clinical development.
• – The company will use the funds to further support its goal of creating innovative cancer treatments through its pioneering ADC technology.